Zydus, Guardant Health to promote Guardant360 genomic tests for cancers in India and Nepal
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Tatva Chintan Pharma Chem has reported total income of Rs. 97.42 crores during the period ended September 30, 2023
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Lyka Labs has reported total income of Rs. 28.23 crores during the period ended September 30, 2023
Morepen Laboratories has reported total income of Rs. 425 crores during the quarter ended September 30, 2023
The company has posted net profit of Rs.978.93 crores for the 6 months period ended September 30, 2023
Lincoln Pharmaceuticals has reported total income of Rs. 164.68 crores during the period ended September 30, 2023
Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023
The company has posted net profit of Rs.115.08 crores for half year ended September 30, 202
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Subscribe To Our Newsletter & Stay Updated